Gleevec, also known as imatinib mesylate, is a very effective drug for gastrointestinal mesenchymal tumors and acute lymphoblastic leukemia, and is generally indicated for high-risk mesenchymal tumors, including gastric mesenchymal tumors and intestinal mesenchymal tumors, to prevent recurrence and metastasis. At first, this drug was mainly used for acute lymphoblastic leukemia, but later it was found to be effective for mesenchymal tumors as well. In addition to chemotherapy, targeted drug therapy is also very effective, and there are also bone marrow transplantation methods. In the case of mesenchymal tumors, the nature of the tumor may be determined by surgical resection at first, and then the risk level will be determined by immunohistochemistry results, and then the need for Gleevec treatment will be considered.